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    Abstract 
 
This paper looks into the reasons why the Food and Drug 
Administration did not declare themselves as having 
regulatory power over human organs that would be used 
for medical purposes such as organ transplants and 
discusses why the FDA should take over this regulatory 
power and the various arguments that could be used 
towards taking over this power and the various possible 
benefits of having organs under the same regulatory 
control as all the other human material/parts being 
regulated for medical purposes.  
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I. INTRODUCTION  
As are many things that you come across in life the Food and Drug 
Administration (FDA) was created in order to serve a purpose, this purpose is to help 
protect the public health. This is done through the regulation of various materials and 
products used in and on the human body.  In addition to things like food and cosmetics 
the FDA’s regulatory power also stretches out to the medical arena thus allowing them to 
regulate not just over drugs and vaccines but also medical uses of actual elements of 
human and animal bodies.  
Although the FDA has gone forth and accepted regulatory power in terms of 
certain aspects of the human body for medical purposes there is still more that they could 
and should do in this area. It is no question that we have come a good way in terms of 
medical advancements with vaccines and other medicines but it is obvious by the many 
different diseases and viruses that continue to plague mankind that we still have a way to 
go. Though there may still be a vast amount that can be done through non-synthetic 
chemicals and mixtures created within a lab, truthfully, some of the things that may prove 
to be the best answers and cures for the human body probably come from none other than 
the human body itself rather than a non organic chemical concoctions.  
Although it may not always work the way we would like and it can sometimes 
only take effect over the course of generations the human body is an amazing structure of 
organisms, and has the capability to evolve and adapt to surroundings just like we have 
noted with many other species of animals. In fact the human body in itself is extremely 
complex and is technically still more advanced than our current scientific development. It 
is because of the vast array of possibilities that could possibly be addressed that the FDA    
should expand their regulatory control as a step in the right direction towards the possible 
creation of programs and further research in order to help further humanity in realm of 
public health.  
Although we do thankfully have medicines and vaccines to help us survive our 
bodies in general have become more tolerant towards certain things that once could kill 
us. Additionally, there are some things that at one point in time were not as harmful in 
our bodies as they are now, another result of gradual change/ adaptation of the human 
body. One example of this would be the consumption of raw meat, which can cause 
salmonella poisoning. Although eating raw meat now could actually be deadly, though 
some people can still eat things like steak tar tare, humans are omnivores and thus can, 
and for many do, eat meat. Whether one believes in evolution or creationism you cannot 
deny the fact that we did not always have the technology and knowledge that we have 
now and thus the way we cook food currently has probably not always been the case. In 
the past people were more than likely consuming a hefty amount of bacteria from 
undercooked food but because of the body’s ability to “evolve” and build up an immune 
system people more than likely did not have the same reaction to eating undercooked or 
raw food that many people have now.   
Although there are many things that could be done to help push us in the right 
direction towards furthering scientific development and public health, the first thing that 
needs to be done is make the current system we have as efficient as possible. In terms of 
the FDA this means finally filling in the missing gap in the regulatory power when it 
comes to materials from the human body.      
II. FDA REGULATION OF ORGANS 
Although tissues fall under the realm of body elements that the FDA has taken 
regulatory power over when it comes to Organ Donation this is an area that FDA has left 
in the hands of another organization, The Health Resources and Services Administration, 
the federal agency that presides over health care services. Although the HRSA’s main 
function has to do with health care, which does align with the issue of organs donation, 
there is one fundamental problem with the current setup.  
As aforementioned it is the FDA not the HRSA that has regulatory power when it 
comes to tissues but not organs, this split seems to suggest that they are different enough 
from each other that it could actually make sense that two different agencies have 
regulatory power over them, but in reality organs are not things that are completely 
separate from body tissues. Human organs and body tissues are not just two groups of 
things that merely come from the same place, the human body, human organs are actually 
comprised of tissues and cells. Thus the separation of Organs from tissues causes a 
separation in the agency involved with the regulation of the individual parts and the 
agency which is involved with the regulation of what the separate parts are able to come 
together and form as a whole.   
Under the Federal Food, Drug, and Cosmetic Act there are three routes that the 
FDA could try and take in order to ague that human organs undoubtedly fall under their 
regulatory powers. Since the Federal Food, Drug, and Cosmetic Act gives them 
regulatory power over drugs, devices, and biological products the introduction of a valid 
argument that human organs can technically be seen as falling under the definition of a 
Drug, Device, and/or Biological Product would give them the ability to regulate the use    
of them in organ transplantations as well as the extraction and storage procedures 
involved with organ transplantation as well.  
A. ORGANS AS DRUGS  
Out of the various things that the FDA could use to declare their ability to 
regulate human organs and procedures used in organ transplants the general thought that 
the argument that this power could be gained through the FDA’s ability to regulate drugs 
is one that on its face may sound ridiculous but in reality is not so much.  
In the textbook “Food and Drug Law: Cases and Material” it is mentioned that 
one of the previous administration’s interpretation of the term drug made it uncertain as 
to whether the term could include human organs or not. The interpretation they were 
referring to stated that “ a drug… is a chemical or a combination of chemicals in liquid, 
paste, powder or other drug dosage form that is ingested, or instilled into body orifices, or 
rubbed or poured onto the body in order to achieve its intended medical purpose.”
1 Under 
this interpretation of the term drug it does seem very understandable how there could be 
uncertainty towards whether the FDA had the power to regulate organs. In fact, it seems 
like any argument for regulatory power by the FDA would be a stretch, but an argument 
based on this interpretation is actually possible.  
According to Merriam-Webster’s dictionary the word instilled is defined as 
meaning both “to cause to enter drop by drop” and “to impart gradually.”
 2 Although the 
drop by drop wording does not seem as if it would not advance the argument for 
regulating human organs , the second definition, “to impart gradually”, which appears to 
                                                 
1 Peter Hutt, Food an Drug Law: Cases and Materials, 939 (Robert C. Clark ed., Foundation 
Press, 2007) (1980)  
2 Merriam Webster Online, Instilled, http://www.merriam-webster.com/dictionary/instilled    
be the definition the FDA was using for the term, does seem to work. Since an organ 
transplant is not a five minute procedure in which the doctors just drop the organ into the 
body and it attaches to the body on its own like a parasite, but rather one where they have 
to individually connect all the tissues and blood vessels in order for it function within the 
recipients body this portion of the interpretation of the term drug easily engulfs organ 
transplants. The only real difficulty when dealing with this interpretation of the term drug 
comes from the beginning of the interpretation, where it confines drugs to chemicals or a 
combination of chemicals in liquid, paste, powder, or other drug dosage form. This 
sentence of the interpretation seems to pretty much knock out all possible arguments that 
a human organ could fall under the term drug. The first part of the sentence “ Chemical or 
chemical compound” is not that hard to come up with an argument for. The FDA could 
push the argument that technically everything in the world is basically comprised a 
different complex chemical compositions and thus human organs are comprised of a 
chemical combination. This statement is one which scientists have been making for a 
good deal of time; in fact you can actually look up the chemical compositions of some 
organs online. Although this part of the argument is not that hard the real challenge 
comes about when looking at the end of the sentence which states that the chemical or 
chemical compound must come in a “liquid, paste, powder, or other drug dosage form”
3. 
The only way to possibly make human organs fit into this interpretation of drugs would 
be to somehow manage to argue that each human organ, these complex chemical 
compositions, as a whole comprise what can be seen as a dosage of the chemical 
compounds or organ; an argument that probably is even more confusing than it sounds on 
its face.  
                                                 
3 Hutt, Supra note 1, at 939    
Though one could try and force there way through an argument that under the 
aforementioned interpretation of the term drug human organs would apply and thus they 
could be regulated by the FDA under the power to regulate drugs given to them through 
the Food, Drug, and Cosmetic Act. This argument would be a very tricky one to make 
and does not seem like one that would really hold up if challenged.   
Despite the fact that under the old interpretation of the term drug it seems as if 
human organs would not fit within the regulatory powers of the FDA this does not 
destroy the argument for regulatory power under their authority to regulate drugs. In 2007 
the Food and Drug Administration released their latest amended definition for the term 
drug. This new definition seems to completely take away any uncertainty as to whether 
the FDA could regulate human organs based solely on their ability to regulate drugs 
under the Food, Drug and Cosmetic Act.  
The 2007 definition of the term drug states that “the term "drug" means (A) 
articles recognized in the official United States Pharmacopeia, official Homeopathic 
Pharmacopeia of the United States, or official National Formulary, or any supplement to 
any of them; and (B) articles intended for use in the diagnosis, cure, mitigation, 
treatment, or prevention of disease in man or other animals; and (C) articles (other than 
food) intended to affect the structure or any function of the body of man or other animals; 
and (D) articles intended for use as a component of any articles specified in clause (A), 
(B), or (C) under the definition from drug given in § 201 it appears that organs would 
easily fit into the description of what can be counted as a drug for purposes of FDA 
regulation under the Food and Drug Act”
4.   
                                                 
4 21 U.S.C. 321 § 201 (g)(1)    
Since the human organs in a organ transplant are for the purpose of replacing the 
malfunctioning organ in the person’s body it can easily be stated to be for the purpose of 
curing the transplant recipient of the illness that they have or at the very least  as a 
treatment for it and thus would easily fall under §21 (g) (B). Additionally, since a 
diseased or malfunctioning organ is chemically different and than a healthy organ and 
acts different than a healthy functioning organ
5, the transplant of a healthy human organ 
into someone’s body can be stated to affect the function of the sickly persons body and 
would thus also fit under §201 (g) (C).  Thus with the new definition of the term drug it 
appears that the FDA technically could take control of the regulatory power over human 
organs and organ transplants under their power to regulate drugs.  
B. ORGANS AS DEVICES 
When the original question of whether the FDA could regulate organs was being 
looked into the FDA definition of the term device seemed to pretty much bar them from 
taking regulatory control of human organs under that portion of their regulatory powers. 
The definition that was being used at the time for the term device was “ ‘an instrument, 
apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar 
related article… which is… intended for use in the diagnosis of disease or  other 
conditions, or in the cure, mitigation, treatment, or prevention of disease’ or which is 
                                                 
5 According to the Institute of Liver Diseases of the General Hospital of Beijing Military Region 
liver diseases as well as certain nutritional situations change the chemical composition of a liver. 
Institute of Liver Diseases, The chemical composition of the liver, 
http://www.ganbing.com.cn/YLW21.htm    
‘intended to affect the structure or any function of the body,’ and ‘which does not achieve 
any of its principal intended purposes through chemical action within or on the body’”
6. 
Although human organs could fit within the first part of the definition since 
organs used for an organ transplant could be stated to be an implant, since they are put 
into a body that was not the original body that the organ came from, that was for the 
purpose of curing the patient of the illness caused of having a diseased or bad organ in 
their body, the end of the definition, which states that the primary purpose cannot be 
obtained through chemical action within the body seems to go against use of the term to 
regulate human organs.  
As stated within the “Food and Drug Law” text book it appears that the term was 
probably defined in a way that only man made or partially man made objects would be 
able to fit under this category. Although the text can be read to reject the argument that 
human organs cannot be regulated by the FDA under their power to regulate medical 
devices, based upon the text of the originally used definition this would not necessarily 
apply to all human organs.  
Where as livers, whose main functions are to regulate the chemical levels within 
ones blood and to create and excrete bile to break down fats
7, would be disqualified from 
being something that the FDA could regulate under the aforementioned definition of 
devices, hearts are organs that pump blood throughout the body, a process that is done as 
a result of electrical impulses. Therefore, unlike the Liver, which actually produces a 
product and thus serves its primary purpose through chemical action the heart is  “ a 
                                                 
6 Hutt, Supra note 1, at 940 
7 Lucile Packard Children’s Hospital at Stanford, How the Liver Works, 
http://www.lpch.org/diseasehealthinfo/healthlibrary/digest/liverant.html    
muscular organ”
8 that continuously pumps blood throughout the rest of the circulatory 
system, which carries blood to the entire body. “An electrical system regulates your heart 
and uses electrical signals to contract the heart's walls. When the walls contract, blood is 
pumped into your circulatory system. A system of inlet and outlet valves in your heart 
chambers work to ensure that blood flows in the right direction.”
9   
Despite the fact that an argument could be made under the old definition of the 
term devices for the FDA to have regulatory power over human hearts, separating them 
from other organs that we use in organ transplants would have more than likely been a 
worse idea than the separation of organs in general from body tissues. Thus, it is very 
understandable why the FDA probably would have not even wanted to try and go that 
route.  
Though today, after a few decades, many things have changed in the world 
including some of the definitions used by the FDA, the argument that they could include 
human organs is still at the same place that it was back when the discussion of  the FDA’s 
possible authority first came into play. Currently, the amended definition for the term 
devices that the FDA is using states that a device is “an instrument, apparatus, 
implement, machine, contrivance, implant, in vitro reagent, or other similar or related 
article, including any component, part, or accessory, which is— (1) recognized in the 
official National Formulary, or the United States Pharmacopeia, or any supplement to 
them, (2) intended for use in the diagnosis of disease or other conditions, or in the cure, 
mitigation, treatment, or prevention of disease, in man or other animals, or (3) intended to 
affect the structure or any function of the body of man or other animals, and which does 
                                                 
8 National Heart Lung and Blood Institute Disease and Conditions Index, How the Heart Works, 
http://www.nhlbi.nih.gov/health/dci/Diseases/hhw/hhw_whatis.html 
9 Id    
not achieve its primary intended purposes through chemical action within or on the body 
of man or other animals and which is not dependent upon being metabolized for the 
achievement of its primary intended purposes.”
10  Although the definition seems to have 
been expanded upon a little and is not technically the same definition as before, it still 
includes the statement about  the primary intended purpose not being able to be achieved 
through chemical action with the body. Thus the chance that the argument that the FDA 
could regulate human organs in general under their ability to regulate medical devices 
does not seem like one that would truly hold.  
C. ORGANS AS BIOLOGICAL PRODUCTS  
The last of the three main arguments towards why the FDA should be able to take 
regulatory control over human organs for the purposes of organ transplants deals with the 
fact that human organs could be seen to fall under the category of biological-
products/biologics.   
The Public Health Services Act, which the FDA looked towards when thinking 
about their ability to regulate human organs, authorizes the licensure of   “biological 
product”  which the act stats to include “any virus, therapeutic serum, toxin, antitoxin, 
vaccine, blood, blood component or derivative, allergenic product, or analogous product, 
or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic 
compound), applicable to the prevention, treatment, or cure of a disease or condition of 
human beings.”
11 When looking at the general text of this Act the fact that it includes 
blood, blood products, or analogous products,  seems to give the initial allude towards the 
                                                 
10 21 U.S.C. 321 § 201 (h) 
11 42 U.S.C. 262 (i)    
idea that that the concept of human organs being looked at as biological products is one 
that would work. Although based upon the text alone this seems to be an appropriate 
route to take in an FDA claim to regulatory power over human organs, the FDA actually 
decided in the past that the language of the document in fact did not give rise to this 
claim.  
The decision of the FDA that the definition of biological products did not 
encompass human organs was based on a combination of the text of the definition and  
the legislative history of the 1970 amendment. According to Hutt’s “Food and Drug 
Law” the FDA felt that a narrow interpretation of the term analogous should be read into 
the act. This was based upon the fact that in the 1970 amendment both the terms “blood” 
and “blood component or derivatives” were added to the act due to the fact that when the 
1902 Act was first promulgated the process behind blood transfusions was not known but 
since then had been discovered and were no longer experimental treatments, where as 
organ transplants, on the other hand, were still experimental as a result the FDA felt that 
the term analogous products should not encompass them.
12 Additionally, the decision to 
not count human organs as analogous products to blood products seemed to be further 
backed by the fact that in 1984 Congress passed the National Organ Transplant Public 
Law 98 - 507. 
Looking back on the whole situation with biological products it seems as if the 
FDA may have possibly read too much into things.  Although organ transplants were still 
experimental procedures at the time the Public Health Services Act was enacted and 
congress did not specifically put organs into the list of possible licensures, this does not 
mean that they did not want them to fall into the biological product category. Although 
                                                 
12 Hutt, supra note 1, at 940    
the act listed things that were authorized for licensure no actual definition of biological 
products were given in it. The fact that the act did not set provide a term or definition for 
the category but rather gave an incomplete list seems to say that it was still open to be 
extended upon.
13 Since organ transplants were still experimental procedures it may have 
simply been better to leave them off the list but leave room for them to still fall into that 
category rather than put them on the list only to realize that organ transplants in fact were 
a bad idea.  
As for the fact that not long after the Public Health Services Act was enacted 
congress also enacted the National Organ Transplant Pub L. 98-507 this does not seem to 
support the argument that congress meant for the FDA not to have regulatory power over 
human organs in terms of organ transplants either. In fact, when looking at the document 
the Public Law seems to lean more towards the exact opposite argument. When you read 
through Public Law 98 – 507 the over arching purpose of it appears to be leaning more so 
towards the creation of a task force for the purpose of research and gathering information 
in regards to organ donation rather than trying to set up another agency. In the Pub. L. it 
describes the role of the task force that is put in place and when reading these 
descriptions you come across the same types of words and phrases over and over again, 
things like: “ conduct comprehensive examinations” and “Prepare the assessments”. 
Additionally the act explicitly states a date in which the task force is supposed to 
terminate.  
The portion of the Public Law that addresses administration only does so to state 
that they are to maintain an administrative unit to do things such as “ coordinate with the 
                                                 
13 Although the language in the Public Health and Safety Act did not set a definition for 
biological products but rather gave authorization for licensure of certain things, the language used 
is now stated in 42 USCS § 262 (i) to be the FDA definition for biological product.    
organ procurement activities … conduct a program of public information to inform the 
public of the need for organ donations…provide technical assistance to organ 
procurement organizations receiving funds under the Organ Procurement and 
Transplantation Network” and “submit to congress an annual report of the status of organ 
donation and coordination services.”
14 
The way things got to be where they are today in terms of human organs seems  
like it is probably more of a result of the fact that the FDA could of and should have 
taken over the regulatory control of human organs to be used for organ transplants but 
failed to do so.  
In the law there have been various cases in which the courts have allowed for the 
expansion of the reading of an act as times brought about new developments. Congresses 
addition of the term blood can arguably be said to show that Congress technically 
intended for the scope of this act to grow as new procedures that fell within the realm of 
the definition given for the category were fully developed. Thus, the fact that the PHS 
Acts 1970 Amendment did not include the term organs but rather just added blood and 
blood products still leaves an argument for the FDA to have regulatory power over 
human organs, an argument that would probably hold today.  
D. TYING THE THREE TOGETHER  
Despite the fact that technically the argument for regulating human organs under 
the term devices does not seem to have much validity for any organs other than hearts, 
when looking at the aforementioned arguments/ routes that the FDA could take to lump 
in organs under their regulatory powers the basic fact that each one in it’s own way could 
                                                 
14 National Organ Transplant, Pub. L.  98 - 507    
technically give rise to some sort of organ regulation adds to the overall argument that the 
wrong agency has been regulating this matter.  
Although initially the FDA did not want to regulate under any of these three terms 
because of the possible reach and the problems that that could possibly cause as a result
15, 
today the FDA should go this route like they have done since the 1970’s with human 
tissue and stem cells.  
Tissue transplants and tissue banks were originally things that the FDA did not 
regulate but over the course of time as the methods and procedures advanced and the 
demand rose this changed. As tissue banks became an independent industry the FDA felt 
a need for regulation.
16  Although nearly two decades past between the time when the 
FDA began contemplating regulation and the 1993 interim final rule that they published 
“requiring the screening and testing of tissue donors for certain transmissible diseases 
such as HIV and hepatitis, as well as the screening of donors for behavioral risk 
factors”
17, in the end they did assert regulatory control over it.  
The FDA should do the same thing they did with human tissue to human organs 
and take oven the regulatory control under both their ability to regulate the approval of 
biologics as stated in the Public Health and Service Act and through its power under the 
Federal Food and Drug Cosmetics Act to regulate drugs.  This route towards regulating 
human organs would be the same as how the FDA claims authority to regulate most other 
biologics.
18 
                                                 
15 Hutt, supra note 1, at 944 
16 Hutt, supra note 1, at 942 
17 New York Organ Donor Network, The History of Tissue Transplantation, 
http://www.donatelifeny.org/transplant/tissue_history.html 
18 “FDA's regulatory authority for the approval of biologics resides in the Public Health Service 
Act (PHS). However, biologics are also subject to regulation under the Federal Food, Drug, and    
According to the FDA website “Biological products can be composed of sugars, 
proteins, or nucleic acids, or a combination of these substances. They may also be living 
entities, such as cells and tissues. Biologics are made from a variety of natural 
resources—human, animal, and microorganism—and may be produced by biotechnology 
methods.”
19  As shown by the FDA’s description of Biologics the FDA already regulates 
numerous biological products that come from the human body . The FDA’s Center for 
Biologics Evaluation and Research (CBER) regulates “blood and blood components”, 
“gene therapy products”
20, and “human tissue and cellular products used in 
transplantation”; and the Center for Drug Evaluation and Research (CDER), also found 
within the FDA, regulates biological products such as  “monoclonal antibodies designed 
as targeted therapies in cancer and other disease cytokines (types of proteins involved in 
immune response)”, “growth factors (proteins that affect the growth of a cell)”, “enzymes 
(types of proteins that speed up biochemical reactions), such as thrombolytics (used to 
dissolve blood clots)” and “immunomodulators (agents that affect immune response).”
21 
Although the biologics listed that the CDER regulates are biological products that they 
generally produce through the use of biotechnology, they are still biologics that 
technically originated from the human body. Based on the FDA description of Biologics, 
as well as the fact that tissues and cells fall under this category, human organs should fall 
into this category as well. 
                                                 
Cosmetic Act (FD&C Act) because most biological products also meet the definition of "drugs" 
cited within this Act.” U.S. Food and Drug Administration, FDA 101: Regulating Biological 
Products, http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048341.htm 
19 U.S. Food and Drug Administration, FDA 101: Regulating Biological Products, 
20 “FDA defines gene therapy products as products containing genetic material administered to 
modify or manipulate the expression of genetic material to alter the biological properties of living 
cells” U.S. Pharmacopeia, Definition of Terms: Gene Therapy, 
http://www.pharmacopeia.cn/v29240/usp29nf24s0_c1046s118.html 
21 FDA 101, supra note 19    
E. THE PROGRESSION OF MEDICINE THROUGH TIME  
As aforementioned in Section II (D) of this paper some of the biological products 
that the FDA regulates are human based products developed in laboratories. Although 
one may think that the fact these specific products are not all taken directly from a human 
but rather created by scientists that the FDA’s ability to regulate them should not have 
any bearing on whether or not the FDA should  be able to take regulatory control over 
human organs that are to be used for organ transplants, the FDA’s regulatory power over 
them actually adds to the argument.  
As time progresses so does science. Every day scientists are working towards 
more and more technological advances. One specific goal that scientists have been 
working towards is the ability to grow organs. This ability would drastically reduce or 
eliminate the need for people to donate organs to save the lives of those with 
malfunctioning ones. Although it may seem as if the ability to grow organs is a long way 
away the truth of the matter is that it has already begun. Over the last decade there have 
been successes when it comes to growing organs. In 2006 North Carolina a group of 
scientists lead by Dr.’s Anthony Atala, the “director of the Institute of Regenerative 
Medicine at Wake Forest University Baptist Medical Center”, and Alan Retik, the “chief 
of urology at the Children's Hospital in Boston” succeeded in growing human bladders to 
be transplanted into seven different patients.
22  
                                                 
22 Logan Ward, Popular Mechanics, Beyond Transplants: Growing Organs in the Lab, 
http://www.popularmechanics.com/science/4212851    
The patients in Dr. Atkas’ study were all suffering from a disease called spina 
bifida, “a congenital birth defect that stunts brain and spinal cord development”
23 that is  
“caused by the incomplete closure of the embryonic neural tube.”
24   One of the various 
affects of this disease is that it can put into individuals at risk for kidney damage and can 
result in problems with urinary control.
25  Generally the procedure for treating patients 
with this diseased bladders involves surgeons taking some of a patient’s own intestinal 
tissue and using it to repair the bladder but this treat is stated to lead to complication and 
can even cause cancer.
26  “In the new procedure, doctors extract muscle and bladder cells 
from a small piece of the patient's own bladder. The cells are grown in a Petri dish, then 
layered onto a three-dimensional mold shaped like a bladder. In a few weeks, the cells 
produce a new bladder, which is implanted into the patient. Within a few more weeks, the 
new bladder has grown to normal size and has started functioning.”
27 After the bladder is 
functional it can be transplanted into the patient. Additionally, “Because the bladders are 
grown from a patient's own cells, there is no risk of rejection, as in a traditional 
transplant.”
28 
The 2006 case in which Dr. Atala grew human bladders is just one case of 
growing human organs. In fact, Dr. Atala and the Wake Forest Institute for Regenerative 
Medicine are working on growing “22 different tissues and organs including things such 
as the heart, liver, kidney, pancreas, and wind pipes.” Additionally, in a 2009 interview 
                                                 
23 Haddam Neck, CNN, Doctors grow organs from patients’ own cells: Seven living with 
bladders from new process, 
http://www.ivanhoe.com/channels/p_channelstory.cfm?storyid=22770 
24 Wikipedia, Spina Bifida, http://en.wikipedia.org/wiki/Spina_bifida#Signs_and_symptoms 
25 Neck, supra note 23 
26 Ward, supra note 22 
27 Neck, supra note 23 
28 Neck, supra note 23    
Dr. Atala stated that the next trial that the Wake Forest Institute is going to undergo will 
be the growth of skin
29, which is technically an organ.
30  Dr. Atala states that one of the 
procedures that they are “using to make skin involves actually taking a skin graft and 
then placing it in a bioreactor, and then allowing it to grow in the bioreactor,
31 making 
larger sheets.”
32   
With science rapidly advancing to the point in which tissues and cells can be 
taken and used to grow organs to be used for organ transplants the need to consolidate the 
regulatory power in regards to regulating the use of components of the human body that 
are used for medical purposes grows greater. Having a split in the agencies with 
regulatory power could create havoc in terms of trying to continue to move forward and 
could stunt scientific and medical advancement. This fact, that the split in regulatory 
powers can is burdensome, is one that has been admitted to by the agencies themselves in 
past final rule. In the 2007 joint ruling issued by them, which stated that blood vessels 
extracted with organs for organ transplant purposes would solely by under the regulation 
of the HRSA, the two agencies state in that the summary that the purpose for this is that 
“this change will eliminate the burden resulting from an organ procurement 
organization's efforts to comply with both FDA and HRSA rules with respect to blood 
vessels (FDA jurisdiction) and organs (HRSA jurisdiction).”
33 
As science continues to advance the problem that was brought up by the agencies 
in this final rule, as well as final rules in the past, will continue to arise. Therefore in 
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order to help ensure efficiency and help promote the continuous advancement of medical 
treatments and technology jurisdiction over the regulatory power of human organs should 
lie in the hands of the FDA so that the same agency has regulatory control over the 
medical use of stem cells, blood, blood products, tissues, organs, and the biological 
devices that are used in the storage and the in vitro generation of the human body 
products.
34 
III. THE GOOD THAT CAN COME ABOUT  
There are various reasons as to why it would be better for the Food and Drug 
Administration to have regulatory control over the use of human organs for medical/ 
transplant purposes. First there is the fact that by compiling everything under the 
regulatory power of the FDA we would sidestep any future agency squabbles over who 
has regulatory control over what, if ever, any new medical information were to come to 
light. Considering the fact that tissues and cells, both of which are under the regulatory 
control of the FDA, are now being used to successfully grow organs this is something 
that is very important. As more and more organs are grown rather than just simply 
extracted from a living or deceased donor, the likelihood of agency clashes will increase. 
Additionally the consolidation of all human parts that are used for medical purposes 
under the FDA would help reduce possible confusion amongst scientists and thus that 
may be caused by the fact that they are currently being regulated by two different 
agencies.  
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   An overall lack of confusion and agency clashes could also help lead towards 
further advancements towards the regulation of human organs and biological materials 
from human bodies in general and possibly even the development of a new system in 
which we go about collecting cell and tissue samples as well as organ donor information 
which people would actually be willing to partake in.  
In “ 1993, FDA issued an ‘Interim Rule for Human Tissue for Transplantation’ 
(58 FR 65514) which required donor screening, infectious disease testing, and record 
keeping to prevent the transmission of infectious diseases through human tissue used in 
transplantation. The regulation applied to ‘conventional’ human transplanted tissues 
(musculoskeletal, skin, ocular) but did not encompass tissue used in cellular therapies. 
Additionally, the regulation excluded semen and other reproductive tissue, human milk, 
bone marrow, and vascularized human organs, such as heart, kidney, liver, lung and 
pancreas.”
35 Although testing organs that are to be transplanted in the same way that the 
FDA’s rule required the testing of tissues would not really be a feasible idea due to the 
time it takes to test for diseases in relation to the need for organs and the short time span 
which many organs are able to be stored and still be transplanted into someone without 
any serious detriments or complications, if the FDA had regulatory control over organs 
the information taken from the testing of the different tissues could have been used to 
gain knowledge on whether the possible organs that someone donated might possibly be 
bad. For example, if someone is an organ donor and had previously donated tissue 
samples, if the tissue samples were tested and found to have a disease such as H.I.V. then 
this information would be put into the records of the tissue sample results and if 
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something fatal were to happen to the person they Doctors would not need to even 
attempt to remove the organs from the body because they would be red flagged to show 
that this organ donor had a fatal disease that would infect the transplant recipient.  
If a system was in place in which the results of the tests of all the people who 
donated blood, cord blood, bone marrow, tissue, etc. were kept in a registry as to 
eliminate people with certain illnesses that would be transferred in a transplant then that 
would help cut down on the possible risks of getting a transplant. Although there is 
always the possibility that someone contracted something since they last donated the 
ability to rule people out without having to test them on the spot for diseases could make 
the system more effective because some people would not need to be retested because 
they would already be ruled out from donating to a healthy person.  
Although there are procedures in place to help prevent the transmission of 
diseases through organ transplants they still do not effectively provide safeguards against 
all infectious disease. With both new diseases and new strands of older diseases infecting 
people it is important to have some sort of system to help make things more efficient. For 
example, in order to try and prevent the spread of diseases such as H1N1 “the United 
Network for Organ Sharing, the nonprofit that operates the nation's organ-transplant 
system, recommended that lungs and intestines from donors known to be infected with 
the H1N1 swine-flu virus not be used because of infectious risk, and said the lungs of 
donors with seasonal influenza should also be avoided.”
 36 With the number of organs 
that are being extracted from the corpses of organ donors to be transplanted into parents a 
great deal of time and money will be spent trying to test for these additional things when 
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some of it could have been saved by the mere creation of a database in which organ 
donor health information was kept. If there was one central database storing such vital 
information people who were treated for either H1N1 or seasonal influenza could be red 
flagged right away.  
This fear that even today with our technological capabilities that we might still 
transmit diseases through organ transplants is one that is shared by numerous groups. 
According to the Wall Street Journal  “In a new report commissioned by the U.S. 
Department of Health and Human Services, experts from the CDC and other government 
agencies warn that a patchwork of regulations and voluntary efforts by groups such as 
Unos aren't sufficient. The report, ‘Biovigilance in the United States: Efforts to Bridge a 
Critical Gap in Patient Safety and Donor Health,’ calls for the creation of a centralized 
system to monitor blood, organ and tissue safety, gather reports of illness or adverse 
reactions among recipients, and quickly trace organs and tissues from donors who are 
found to carry infectious diseases.”
 37 
With living organ an tissue donors there is generally more time to do extensive 
testing to help ensure that the donor will not be passing on some sort of disease to the 
recipients but since the turn around for the transplantation of organs and tissues from 
deceased donors is shortened by the fact that the donor is dead and thus the organ and 
tissues must be extracted right away the ability to easily look up the donors information 
from their latest blood donation and also the ability to track every person that receives 
anything from the donor, whether it be tissue or an organ, would allow to help prevent the 
spread of disease. And even if by chance the deceased donor turns out to have had a 
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disease that could spread to the recipients of the transplants by having the information on 
both organ and tissue recipients easily accessible once one person is found to have gotten 
something from the transplant than the rest of the recipients can be checked immediately 
and if they have not contracted it than maybe something could be done to ensure that they 
do not get sick as well.  
For example if tissue and organs are extracted from a corpse and are used for 
grafts, liver, heart, kidney, lung, and intestine transplants and then it is found that this 
person had cancer that had not been previously detected and that this could spread 
throughout the people that received the transplants they could possibly start the patients 
on treatment early on so that it does not costs them their lives or if possible give them a 
new organ transplant so that they will receive what is hopefully a healthy organ this time.  
Due to the way things have been handled in the past it is somewhat 
understandable that a unified system of record keeping was never enacted. Unfortunately, 
there have been many cases in which use of such a system would have helped. One 
particular case is that in which a total of 91 different tissues and organs were extracted 
from deceased male donor who while he was living had a history of alcohol abuse. 
Although the donor had initially tested negative for hepatitis C it was later found out that 
he in fact did have the virus. Over a two year period forty different patients received 
transplants originated from the donor, some of which happened after it was discovered 
that he had in fact been carrying the Hepatitis C virus but because there was no system in 
place to keep track of things and allow them to notify the tissue banks that distributed the 
man’s tissues, people who could have avoided receiving the diseased tissues wound up    
getting them transplanted into them. Out of the recipients who received the diseased parts 
eight became infected with the virus, two of which died.
38 
“In the scramble to match sick patients with organs, time is often short, increasing 
the potential for missing a potentially transmissible disease. While organ donors are 
screened for certain diseases, such as hepatitis C and HIV, screening tests are costly and 
imperfect and don't cover every infectious disease.”
 39 Because of this it seems important 
that we take every precaution that we can in order to help make transplants as safe for the 
recipients as we possibly can. Just one single diseased donor, if not caught in time, can 
have a negative reach on the lives and health of over a hundred individuals spread out 
across the world.  
IV. MODEL FOR A NEW GOVERNMENT SYSTEM  
NATIONAL RECORDS DATABASE  
  The best thing to do would be to start things off from the moment an individual is 
born. When children are first born in order to help ensure that the child can be provided 
with effective treatment in the off chance that they get sick as a child, cord blood can be 
taken, tested, and stored. Since cord blood can be affectively stored for at least 10 years 
this would help ensure that if the child got sick within the first decade of their life there 
would be a sample of their own cord blood, which holds stem cells, that doctors can try 
and use to help regenerate any organ or tissue that may be diseased or deteriorating. 
Additionally, if needed it could be used to help grow new organs to be transplanted into 
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the child if  the procedures for growing that particular organ or tissue have been 
somewhat perfected.  
  In addition to storing the cord blood a sample could also be tested to see if the 
child has any infectious diseases to start off with, something that is already done with 
babies anyway.  The data from the tests of the baby’s blood could serve as the first record 
in the child’s national medical file which would be used later on in life if the child ever 
wanted to donate blood, organs, or tissues.  
  In addition to recording information to babies when they are first born, data 
should be recorded from school age children as well. Since in most places school children 
are required to give blood samples in order to go to school these samples can also be used 
to add to the child’s file to see if there are any medical changes that should be taken note 
of. The process of using the results of a persons blood tests to add to their record any 
information that may be vital later on should continue every time someone receives a 
blood test. Additionally, all major illnesses that can cause a potential problem with a 
person’s organs or tissue should be recorded in the database as well. By recording all 
vital information as it is received there will be background information to red flag people 
who decide to become organ donors or whose families decide to donate the persons 
organs after their death that may potentially cause illness in the transplant recipient.  In 
order to help ensure that everyone’s information is being allocated to the right file a 
finger print should taken from all patients the first time they are entered into the system 
and each time after that that they have tests done their finger print should either be 
scanned in or taken manually and sent off to be added into the persons file.    
Maintenance of the National Record Database would not stop with individual 
health profiles but would also maintain information about all organ, tissue, blood, and 
cell donations and transplants made. All material extracted from an individual, either 
living or deceased, for the purpose of transplantation into another individual or to be used 
in the growth of tissues or organs will be given an identification number and tracked.  
Since all individuals living within the country that have seen a doctor will have a 
record and identification number extracted materials are to be labeled by the persons 
identification number and the term for the item extracted from the donor. For tissues, the 
exact number of a tissue extracted shall be taken account of as well.  
   All hospitals and or tissue, cell, or blood banks must maintain records of all 
donations/samples that come through them and where they are distributed to. Even in 
instances in which an organ is extracted from a donor and then transplanted into someone 
within the same facility within a short period of time the information is to be thoroughly 
tracked and then entered into the system.   
If an individual who was deemed healthy and free of any infectious diseases turns 
out to have been misdiagnosed than all transplants done from extractions from that 
individual can tracked and individuals can be tested for the disease and treated early on if 
the disease was contracted. Individuals who receive a transplant would have this 
information marked on their individual file as well along with the tracking information 
for all tissues and organs transplanted into their body as well as blood transfusions.  
POSTMORTEM ORGAN DONOR PROGRAM 
In addition to the general national database in which records on people’s health 
are kept a government sponsored post mortem organ/tissue donor program could be    
implemented as well. Although some of the hospitals and tissue banks involved in this 
could be privately owned the information would be sent into the database in order to 
allow the program to run properly. As a part of the program, people who sign up to be 
organ donors could be paid a small amount of money every six months if they decide to 
continue to be in the program and are eligible to stay in it. Although the participants of 
the donor program would have information in their files on their health already from any 
tests they may have had done at the doctors, one of the requirements of the program 
would be  that the person is tested every six – seven months to ensure that they are not 
carrying certain diseases. Although the tests done on participants would be more than 
what someone would have done at a regular check up the fact that people are getting paid 
to participate in the program would probably diffuse most participants negative feelings 
towards the additional tests. Additionally, the fact that participants would have to get a 
check up and tests every six – seven months will help promote public health.  
  If someone decides not to participate in the program but rather just to simply sign 
the back of their drives license one day, if anything were to happen to them the person’s 
organs would still be extracted but if available any organs received from a program 
participant would be tested and transplanted before the organ from a non program 
member because the risk level of transferring a disease would be lower due to the various 
tests for diseases that the participant would have been required to have done.  
  In order to tell apart people who are and are not a part of the program participants 
should get a special card to carry alongside their driver’s license indicating that they are 
in fact a member of the program. Additionally, participant’s national health records 
should also indicate that the person is a current participant in the program. This way if    
something should happen to someone who is not carrying their card a scan of the person’ 
finger print could be used to identify whether or not they were a member of the program 
or not.  
LIVING DONOR PROGRAM  
In addition to the postmortem organ/tissue donor program, the government could 
also set up a living donor program as well. Like with the postmortem program the 
participants with the living donor program would be required to go through testing to 
ensure that they are eligible to donate but participants in this program would not receive 
payment for donating. Although where as the postmortem program would be put in place 
to help get people to become organ donors so that in the event of their death they would 
be able to help sick people in need of an organ, the living donor program would be 
designed more so to help people who have sickly relatives or friend and would like to 
donate organs to them.  
Since the participants in this program would be alive when they donate, the rules 
for donating through this program would be more stringent than that of the postmortem 
program in that only certain organs, portions of organs, and tissues would be allowed to 
be donated. For example, a person with two working kidneys could donate a kidney but 
only one, and a person who had not donated a portion of their liver in the past seven years 
could donate a portion of that, but unless a person received a heart transplant with a  heart 
that their body was rejecting and they had another one ready for transplant, no one would 
be eligible to donate their heart to someone else through this program.   
In addition to the rules regarding what organs could be donated through the living 
donor program, participants should be required to undergo a psychological evaluation to    
help ensure they are donating their organ for the right reasons and that they are 
psychologically stable enough to go through with the procedure.   
Although there would be no financial compensation for participants of this 
program, in order to get more people to become living donors the program could provide 
the donors with medical protection in case their decision to donate their organ or body 
tissue resulted in them becoming ill late down the line. Since one of the things that can 
dissuade people from becoming an organ donor is the thought that they may one day need 
that organ or portion of an organ they donated, or that the surgery may result in the them 
getting sick, providing a protection to donors in case these events happen would remove 
some of the stress from their decision making process.  
RESTRICTIONS ON THE DONOR PROGRAMS 
Although the creation of  a new system could drastically reduce the time on a 
transplant waiting list to the point in which it does not matter that much who gets which 
set of organs under no circumstances should the organs of a deceased/ cadaver , who 
while alive chose to be an organ donor, go to someone other than the next person in line 
on the list. Although an argument could be made that the family should have a say in the 
recipient at times, just in case someone within the immediate family is in need of the 
organ, this would not be a good idea. The reason for this is that the whole point of this 
system is to help more people live but allowing for the families to choose or even the 
person to make a pre death written decision about this matter completely goes against the 
goal of the program because it could/ and most likely would result in people sacrificing/ 
killing themselves in order to provide a crucial organ to someone they love rather than 
trying to wait on the list for an organ transplant.     
Additionally, no living donor should be paid for donating an organ. Although the 
offering of a monetary payment in exchange for donating an organ could possibly help 
increase the number of people willing to donate a kidney or a portion of their liver to a 
complete stranger in the long run this would not be the best idea. By offering payment for 
organ donation the system would wind up having a sperm bank like effect in which there 
would be an influx of people coming down to donate solely because they are in need of 
cash. Although more organs being donated is a good thing, like as with sperm banks 
individuals who have no business donating will more than likely try and get into the 
program so that they can get paid. Though all donors would be tested before they could 
donate, increasing the number of unhealthy donors who sign up to donate increases the 
chance that something might be missed and wind up infected the organ recipient. This is 
especially dangerous since it takes time for some illnesses/viruses to be detectable, such 
as H.I.V. which can take approximately one - three months before it generally will be 
detected by an antibody test.
40  
Finally, we do not want to push the concept of people selling organs for cash. 
Although it would still be illegal to do so we do not want to take the chance that more 
people will start thinking about going down to Mexico or some other country to try and 
find a shady doctor to remove a kidney or a piece of their liver so that it can be implanted 
into someone who is paying them for it because they do not want to wait for a legal organ 
transplant.  
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MEDICAL ASSURANCE UNDER LIVING DONOR PROGRAM 
Under the current system that we have in place in terms of organ donors living 
donors take up more than just the risk of being injured in the surgery. When people 
decide to become a living organ donor they also wind up putting themselves at risk 
financially, and though there are some policies and practices in effect that help to remove 
some financial burden from the living donor, in the long run a persons decision to donate 
an organ prior to their death could wind up causing them an arm and a leg later on in life.  
  The way organ donation currently works is that initially all the costs are 
put onto the recipient and are billed to their insurance company. Thus the hospital bills 
for the initial tests to see if the donor is a match, whether he or she is even eligible to 
donate the specific organ, and "acquisition fee"
41 for the actual surgery in which they 
remove the organ from the donor are all taken care of by the insurance of the person 
receiving the organ, leaving the donor without an bills in the beginning other than 
possibly the cost of getting to the city and hospital in which all of these things are taking 
place. Additionally, “the medical costs related to the donation procedure and required 
postoperative care are also covered by this fee”.
42  
Although the initial costs for organ donation are taken care of by either the 
recipient’s insurance provider, or in some circumstances by the Transplant Centers Organ 
Acquisition Fund. These things only cover the cost for the actual donation and the 
recovery from the surgery to remove the organ, they do not extend out to help the donor 
in the event that their decision to donate the organ causes illness later on. For example, if 
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someone were to become a living kidney donor and then later on in life something 
happens and the one kidney that they have left starts to fail then the original donor and 
their insurance provider would bare the burden of dealing with the costs of getting 
treatment or a kidney transplant. Things that they may not have had to of dealt with if 
they had not donated their other kidney earlier on in life. Although it could be possible 
that the person could have had kidney failure in both their kidneys there are many people 
who have kidney failure in only one kidney and there is not much of a problem because 
they can continue on with just the other kidney.  
Although just like with the original donee if someone became in need of an organ 
transplant as a result of an organ donation that they made earlier in their life their 
insurance would help take care of the costs this does not save the original donor from 
being financially burdened by their decision to become a living organ donor. If the person 
does not have any insurance at the time they become sick then the there is no one to help 
with the costs of the medical care and unless the person becomes one of the lucky people 
whose care and surgery are paid for out of the Transplant Centers Organ Acquisition 
Fund then they will have to foot the very expensive hospital/ doctors bill all because at 
some point earlier in their life they decided to be a good citizen.  
As for people who do have insurance, although the insurance company will pay most 
of the costs there will still be a financial burden on the person because insurance 
companies charge higher rates for people who have donated organs in the past.
 43 The 
reasoning behind the higher health insurance rates is because people who have donated 
organs are at a higher risk of becoming ill as a direct result of their prior organ 
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donation.
44 Since there are numerous health risks that the donors face after giving an 
organ insurance companies help protect themselves by charging the donor more for their 
insurance, although this is not something that insurance companies should be blamed for 
doing it is something that we should try and fix. The whole point behind the insurance 
business is that insurance companies are paid in order to relieve individuals of the stress 
behind paying large amounts for hospital bills if they get sick, in return for the huge 
financial risk the companies take on for each and every one of their clients the insurance 
companies get to profit off the premiums of those who pay into the policy but never need 
to collect on the more expensive services of the insurance company. The general concept 
behind insurance companies is a good one if you live in a society in which you have to 
pay for health care and the prices for even what are considered relatively small 
procedures can wipe out someone’s entire savings or even make them go bankrupt. 
Additionally, it is understandable that for people who pose and even higher risk of the 
insurance company having to pay a hefty load in medical fees that they charge a higher 
insurance premium, otherwise if an insurance company decided to charge the same for 
everyone no matter the level of risk, unless this standard rate was extremely high, all the 
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high risk patients would switch to that company possibly causing them to hemorrhage 
money due to all the procedures they would wind up paying for.   
Though it is understandable to see why an insurance company would raise the rates 
for people who donated an organ and thus became a higher risk client than they were 
before it is not as clear as to why we let people who donate organs to be put in the 
position in which they have to worry about paying for the costs of medical needs due to 
their organ donation. If things were changed to insure that people who donated organs 
would not have to worry about this it would make things a lot easier and could in fact 
help slightly increase the number of people willing to donate certain organs to people 
they know since they would not have to worry about the financial repercussions in their 
decision making process when deciding whether to donate.  
   Recent legislation has provided some relief by allowing for grant money to be 
allocated towards helping take care of some of the travel and subsistence expenses of 
people who decide to become living donors but this is just short term financial relief, 
something that could and should be fixed.
45 
LEGAL AUTHORITY BEHIND SYSTEM APPLICATION  
In order to try to put a system such as this in place the FDA could draw upon the 
legal authority provided by 42 U.S.C.S. § 264, “Regulations to control communicable 
diseases”, which states that “The Surgeon General, with the approval of the 
Administrator [Secretary], is authorized to make and enforce such regulations as in his 
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judgment are necessary to prevent the introduction, transmission, or spread of 
communicable diseases from foreign countries into the States or possessions, or from one 
State or possession into any other State or possession.”
46 This is the same legal authority 
they drew upon in the 1990’s in order to regulate tissues. 
This would incorporate the vast majority of the system because all the various 
aspects could arguably be stated to be for the purpose of stopping the spread of infectious 
diseases. The database in itself is for the sole purpose of keeping track of people’s health 
in order to ensure infectious organs do not get transplanted into healthy individuals or at 
least individuals who do not have that specific infectious disease. Additionally, the 
general purpose behind both of the donor programs would also be in part for  the purpose 
of stopping the spread of infectious disease because they are set up in order to get more 
healthy people to make the decision to become organ and tissue donors so that the overall 
risk of transferring an infectious disease through transplantations is lowered.  
V. POSSIBLE ISSUES WITH MODEL SYSTEM  
  With the implementation of a new system it would undoubtedly be protested by  
people due to reasons such as fear and genuine disagreement with the system altogether. 
With the aforementioned proposed system there are various reasons why people might 
possibly be  weary or angered by its introduction, some  possibly being valid and many 
probably being “eccentric”.  
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POSSIBLE FEARS  
One possible fear that people may have is that paying people to be postmortem 
donors may result in people participating in the program who shouldn’t all because they 
wanted to make easy money and could thus cause the same result that the system was 
trying to avoid by not paying people to become living organ donors; an increased risk of  
harmful organs being transplanted into a patient.   
Another possible fear that this system could cause is that some people might think 
that by the government having their information and fingerprints on file it would be 
easier for people to be set up for crimes that they did not commit. The logic behind this 
would probably be that since peoples fingerprints will be on file then they could possibly 
be planted at crime scenes. 
Although this may seem like something more so from a horror movie another 
possible fear that people could bring forth concern about could be the issue of people 
taking advantage of this new system by starting to take out people who are organ donors 
in order to either receive the benefit from them being an organ donor or in order to get the 
organs out onto the market sooner.  
Like one should do with any negative emotions surrounding the introduction of 
something new into people lives it would be important that people’s fears were 
addressed. In regards to the fear that the postmortem system could cause an increase in 
risky people becoming organ donors the whole purpose of the 6 month check ups is to 
make sure that the participants’ health is being maintained and that they would still be 
viable candidates for post mortem organ extraction. Since this program is for people who 
are willing to donate their organs after they die the hopes are that these people will live    
for a good deal of time unless an accident occurs. The longer individuals in this program 
live the easier it is to see who lives what type of lifestyle and those whose lifestyle pose a 
threat and cause their organs to be unhealthy would be removed from the program. 
Additionally, even though participants will have routine health screenings on the event of 
their demise they would still be tested for disease. Finally, unlike people who would sign 
up to be a living donor for money, people who participate in a postmortem donor 
program for money would be more likely to try and avoid things that could put them at a 
great risk of contracting something because it would stop the in flow of cash from the 
program.  
 In regards to the fear of making peoples fingerprints available there would be 
some privacy in that the database would be for the purposes of maintaining information 
for health purposes only and would not be shared with general law enforcement agencies. 
Additionally, if technology is at the point in which you can used a scanned image and use 
that to make a phony fingerprint to plant at a crime scene than finger prints probably 
would not be as incriminating as they are today because of the ease in manipulating them 
at crime scenes. Additionally, since it is already not that hard to pull a real fingerprint off 
of something the need for the technology to build a phony fingerprint from a scan  would 
not be needed to set someone up.  
In terms of the pushing organs faster scenario though, although the U.N.O.S list 
may not be highly publicized even with the system that is in play today technically 
someone with money at the top of the transplant list could hire someone to take out 
people who have signed the back of their drivers licenses to be an organ donor in order to 
get more organs flowing in to take care of the people at the top of the U.N.O.S. list.     
Technically what is probably the safest thing for someone who is afraid that they may be 
taken out in order to get more organs for U.N.O.S patients is more people signing up to 
be organ donors when they pass away. With the number of people who die everyday if 
more and more people signed up to be an organ donor the time each patient would spend 
on the waitlist would drop, thus making the need to send someone to help speed the 
process up would not be as necessary.  
RIGHT TO PRIVAVCY ISSUE 
Some people may feel that the creation of a national database in which everyone’s 
medical records are kept would take away peoples rights to privacy because they would 
not have a say in whether or not their information was kept in the file, even if they did not 
plan to donate any organs.  
Unlike with simple medical files, in which you would have to know who you are 
looking for the creation of a database with everyone’s information makes it possible for 
people with access to look up groups of people with specific illnesses with a quick search 
and have a list of individuals almost instantaneously. Thus people’s personal information 
would be available to individuals who do not even know the patient but simply were 
looking into people with a particular illness. This could anger individuals because they 
could possibly be affected if lists of diseased individuals made their way out into the 
public. This has been an issue for numerous groups who have contracted infectious 
diseases because of the fear of what the public would do if lists got out. In the past this 
especially was an issue with people who had contracted H.I.V.  
Although some people may not choose themselves to become organ donors  the 
ability to still have information about them on file is important because there are    
instances in which the families of deceased individuals, upon their deaths, make the 
decision to donate the persons organs so that they could be transplanted into someone 
alive who is in need of a new organ. It is because of instances like this that having 
background eligibility information on everyone becomes important.  
Additionally, the ability to record information on everyone would help allow for 
the program to evolve as time progresses. For example, having knowledge on everyone 
who has H.I.V. could help make it possible to expand the system so that people with 
H.I.V. who are the waitlist for a new organ can get a transplant from a deceased donor 
who was also infected with H.I.V. thus providing more transplantable organs into the 
overall mix.  
  Finally, the government keeping tabs on people with certain illnesses is not a new 
thing. In fact it is already being done to an extent with individuals who are living with 
H.I.V. or  A.I.D.S. In 2006 the federal government introduced the  Ryan White 
HIV/AIDS Treatment Modernization Act of 2006 part of the act set up grants for states in 
which the formula for determining the grants was based upon the number of “names- 
based” cases were reported to the CDC.
47 Although the program may not be in full effect 
with the names of everyone who have been diagnosed with H.I.V. or full blown A.I.D.S. 
most of the states have been participating in this program since early 2007.  
                                                 
47 “Except as provided in clause (ii), the number determined under this subparagraph for an 
eligible area for a fiscal year for purposes of subparagraph (B) is the number of living names- 
based cases of HIV/AIDS that, as of December 31 of the most recent calendar year for which 
such data is available, have been reported to and confirmed by the Director of the Centers for 
Disease Control and Prevention.” 
109 P.L. 415 § 102 (b) (2) (C) (i)    
VI. CONCLUSION 
While we wait for scientist to finish with the work towards the ability to grow 
organs to transplant into individuals and erase the need for organ donors the creation of a 
new effective system for organ and tissue transplants could drastically make a difference 
in the United Stated. By implementing a system in which a deceased person’s vital 
medical information could easily be accessed to help with the decision behind whether 
their organs could and should be transplanted into someone money could be saved on 
pointless tests on the organs of people who would have been ruled out from organ 
donation for a while and lives could possibly be saved.  
Additionally by increasing the number of people who sign up to be organ donors 
we would have the possibility to vastly shorten the waiting time and list for organ 
transplants. Over 107,000 people are currently on the UNOS waitlist waiting to be 
provided with an organ
48 and every day approximately 19 people on this waitlist die 
because they were unable to get an organ transplant.
49  Approximately every 16 minutes a 
suicide takes place resulting to on average about 89 suicides per day.
50 Each day there 
about 4.5 times as many people die from suicide alone than there are people who die in 
need of an organ transplant yet the waitlists for organ transplants are still so high.  
In order to fix the problems in our current system and also help make it so that 
current medical research can continue on smoothly and not have to worry about 
                                                 
48 OrganDonor.Gov, Waitlist Candidates,  http://www.organdonor.gov/ 
49 Richmond Times Dispatch, UNOS Plays National Role In Lifesaving Organ Transplants, 
(March 22, 2009) 
http://www2.timesdispatch.com/rtd/news/opinion/commentary/article/GRAHAM322_20090320-
202112/237209/ 
50 American Foundation For Suicide Prevention, Quick Fact For Suicide Prevention, 
http://www.spanusa.org/index.cfm?fuseaction=home.viewPage&page_id=0D213AD4-C50A-
1085-4DD96CE0EEED52A0    
regulatory battles slowing things down the FDA should take the regulatory power over 
organs that they should have had all along.  
Although efforts are technically being made to try and address the issues that arise 
from this split as long as the split in regulatory powers remain the efforts will never be 
enough. Take the FDA rule 21 CFR 1271 (also known as HRSA 42 CFR Part 121) that 
deals with blood vessels that are recovered with organs and are intended to be used in 
organ transplants. This was issued in order to fix the burden caused due to separate 
regulations towards blood vessels as a part of an organ transplant and than there are for 
ones that are not. Although this rule may have slightly cleared things up for instances in 
which the vessels are extracted with an organ for solely organ donation purposes the issue 
still remains about what is to be done about blood vessels that are removed alongside 
organs and tissues from a deceased donor all of which are for transplant purposes. Are 
only the vessels that were attached to the organ supposed to be deemed for organ 
transplant purposes? Are all the vessels going to be deemed for this purpose and none for 
transplant purposes on their own? Are they supposed to split the amount so some are set 
aside for one use and some for the other? And how would it be addressed if they are set 
deemed to be for one purpose but it then turns out they were not really all needed for that 
purpose and are actually needed for the other purpose?  As long as the split remains 
anything that is issued as a fix to the problem will just merely move the line over a little 
further in one direction or another but will never get rid of it.  
In the end the conclusion is simple. The next joint issuing of a rule that the FDA 
and HSRA issue should be short simple and sweet “ As of (insert future 4 digit date here 
that hopefully starts with 201) the HRSA will no longer have regulatory control over    
organs, all regulatory control for organs from this point forward will fall under the 
powers of the Food and Drug Administration, FDA”. 
 
 
 